drugset / Trial / NCT00012155
Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver
Treatment
Summary
RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the safety of NV1020 in patients who have colon cancer that has spread to the liver and has not responded to previous chemotherapy.
Timeline
- Start
- 2000-10
- Primary completion
- 2002-11
- Completion
- 2009-12
Publications
- Results Kemeny N, Jarnagin W, Guilfoyle B, et al.: Results of a phase I, dose-escalating study of the safety, tolerability and anti-tumor activity of a single injection of a genetically engineered herpes simplex virus, nv1020, in subjects with hepatic colorectal metastases. [Abstract] Ann Oncol 16 (Suppl 2): A-480, ii283, 2005.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NV1020 | Unknown | — | Other |